+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Immune responses to herpes simplex virus in guinea pigs (footpad model) and mice immunized with vaccinia virus recombinants containing herpes simplex virus glycoprotein D



Immune responses to herpes simplex virus in guinea pigs (footpad model) and mice immunized with vaccinia virus recombinants containing herpes simplex virus glycoprotein D



Reviews of Infectious Diseases 13(Suppl. 11): S924-S934



Vaccinia virus recombinants containing the herpes simplex virus (HSV) gene for glycoprotein D type 1 (gD-1) under control of an early (VP176) or late (VP254) vaccinia virus promoter or for HSV glycoprotein type 2 (gD-2) under control of the early promoter (VP221) were studied for their ability to induce protective immunity to HSV-2 in the guinea pig model of cutaneous recurrent disease and the mouse model of fatal disease. Titers of HSV-specific neutralizing antibody were similar in the two groups of immunized animals, but HSV-specific T cell responses were significantly higher in VP176-immunized than in VP254-immunized animals, as determined by lymphoproliferation (P less than .005) and delayed-type hypersensitivity (P less than .01) responses. The reduced responses correlated with poor expression of the gD protein and its impaired processing in infected antigen-presenting cells (splenic adherent and epidermal cells). VP176 immunization protected against primary (P much less than .001) and recurrent (P much less than .001) cutaneous HSV-2 lesions and ganglionic latency (62% protection) in the guinea pig and against zosteriform skin lesions and fatal disease in the mouse. Immunization with VP254 was not protective. In guinea pigs VP221 did not protect against primary HSV-2 cutaneous disease but did reduce the proportion of animals with recurrent disease (P less than .05). This partial protection appears to be associated with the role of type-specific antigenic determinants in gD-2 immunoregulation.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 031806903

Download citation: RISBibTeXText

PMID: 1664130

DOI: 10.1093/clind/13.supplement_11.s924


Related references

Vaccinia virus recombinant that expresses the herpes simplex virus type 1 glycoprotein d gene protects mice against lethal challenge by herpes simplex virus type 1 or herpes simplex type 2 and the establishment of a latent ganglionic infection by herpes simplex virus type 1. Lerner, R A , R M Chanock And F Brown (Ed ) Vaccines 85: Molecular And Chemical Basis Of Resistance to Parasitic, Bacterial, And Viral Diseases; Meeting, 1983 Xxi+407p Cold Spring Harbor Laboratory: Cold Spring Harbor, N Y , Usa Illus Paper 169-174, 1985

Protection of guinea pigs from primary and recurrent herpes simplex virus (HSV) type 2 cutaneous disease with vaccinia virus recombinants expressing HSV glycoprotein D. Journal of Infectious Diseases 155(6): 1188-1197, 1987

Expression of herpes simplex virus 1 glycoprotein B by a recombinant vaccinia virus and protection of mice against lethal herpes simplex virus 1 infection. Proceedings of the National Academy of Sciences of the United States of America 84(16): 5908-5912, 1987

Recombinant vaccinia virus expressing the herpes simplex virus type 1 glycoprotein C protects mice against herpes simplex virus challenge. Journal of General Virology 70: 2587-2594, 1989

Physical mapping of herpes simplex virus coded functions and poly peptides by marker rescue and analysis of herpes simplex virus type 1 herpes simplex virus type 2 inter typic recombinants. De-The, G , W Henle And F Rapp (Ed ) Iarc (International Agency For Research on Cancer) Science Publications, No 24 Oncogenesis And Herpesviruses, Iii Part 1: Dna Of Herpesviruses, Viral Antigens, Cell-Virus Interaction; Proceedings Of The 3rd International Symposium, Cambridge, Mass , Usa, July 25-29, 1977 Lv+580p International Agency For Research on Cancer: Lyon, France Illus P11-32, 1978, 1979

Investigation of the virulence genes of herpes simplex virus type 2 by experimental infection in vivo with defined intertypic recombinants of a virulent herpes simplex virus type 2x an avirulent herpes simplex virus type. Medical Microbiology & Immunology 174(5): 237-248, 1985

Vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D prevents latent herpes in mice. Science 228(4700): 737-740, 1985

Enhancement of protective humoral immune responses against Herpes simplex virus-2 in DNA-immunized guinea-pigs using protein boosting. Fems Immunology and Medical Microbiology 54(1): 18-26, 2008

Antigen-presenting capacity of epidermal cells infected with vaccinia virus recombinants containing the herpes simplex virus glycoprotein D, and protective immunity. Journal of General Virology 70: 2513-2520, 1989

Herpes simplex virus glycoprotein treatment of recurrent genital herpes reduces cervicovaginal virus shedding in guinea pigs. Antiviral Research 10(1-3): 83-88, 1988

Implications for herpes simplex virus vaccine strategies based on antibodies produced to herpes simplex virus type 1 glycoprotein gC immune evasion domains. Vaccine 23(38): 4658-4665, 2005

Immunization with recombinant varicella-zoster virus expressing herpes simplex virus type 2 glycoprotein D reduces the severity of genital herpes in guinea pigs. Journal of Virology 69(12): 8109-8113, 1995

Experimental analysis of the herpes simplex virus infection of mice mainly about the resistance of ska immunized mice against the challenge with herpes simplex virus type 2. Medical Journal of Kagoshima University 28(1): 225-231, 1976

Herpes simplex virus subunit vaccines effect on initial and recurrent genital herpes simplex virus 2 disease in guinea pigs. Pediatric Research 20(4 Part 2): 322A, 1986

Herpes simplex virus infection in guinea pigs: an animal model for studying latent and recurrent herpes simplex virus infection. Infection and Immunity 12(1): 162-165, 1975